The Institute for Clinical and Economic Review (ICER) announced plans to review the comparative clinical effectiveness of ulcerative colitis treatments.
According to a press release, ICER will review the following drugs:
- Vedolizumab, Takeda;
- Infliximab, Janssen;
- Infliximab-dyyb, Pfizer;
- Adalimumab, AbbVie;
- Golimumab, Janssen;
- Tofacitinib, Pfizer; and
- Ustekinumab, Janssen.
ICER’s assessment will be discussed during a June 2020 meeting of the California Technology Assessment Forum.
To read the full press release, click here.